Hejazi N, Hassler W
Klinik für Neurochirurgie, Klinikum Kalkweg, Duisburg, Germany.
Infection. 1997 Jul-Aug;25(4):233-9. doi: 10.1007/BF01713151.
Approximately 34 cases of intracranial tuberculomas with paradoxical response to antituberculous chemotherapy have been documented worldwide. In most of the previously reported cases an associated tuberculous meningitis was reported. The majority of these patients were children or young adults, who had inoperable intracranial tuberculomas located in high risk regions that developed a few weeks or months after the start of an appropriate chemotherapy. Fifty-three percent of the patients recovered completely, 37% improved with mild neurological defects and 10% died. It is interesting that these intracranial tuberculomas developed or enlarged at a stage when systemic tuberculosis was being treated successfully. A recent experience with these potentially curable tumors of the central nervous system is reported. The literature is reviewed, and diagnostic and therapeutic considerations are discussed. The possible immunological mechanisms of this phenomenon are analyzed. In conclusion, patients who are suspected to have a CNS-tuberculosis should receive a prolonged (12-30 months) course of effective antituberculous therapy. The evidence of new intracranial tuberculomas or the expansion of older existing lesions does not indicate the need to change the antituberculous drug program. In such cases systemic dexamethasone as adjuvant therapy for 4 to 8 weeks is worthwhile and effective. Surgical intervention may be necessary in situations with acute complications of CNS tuberculosis, such as shunting procedures for the treatment of hydrocephalus. When the diagnosis is not ensured and there is no response to therapy within 8 weeks, a stereotactic biopsy on a suspected tuberculoma could be performed. If the largest lesion is not located in high risk deep regions of the brain, it could be totally removed surgically. With this combined management, a satisfactory outcome can be obtained in the majority of cases.
全球范围内已记录了约34例颅内结核瘤对抗结核化疗出现矛盾反应的病例。在大多数先前报道的病例中,都伴有结核性脑膜炎。这些患者大多数是儿童或年轻人,患有位于高风险区域的无法手术切除的颅内结核瘤,在适当化疗开始几周或几个月后出现。53%的患者完全康复,37%病情改善但有轻度神经功能缺损,10%死亡。有趣的是,这些颅内结核瘤在系统性结核病得到成功治疗的阶段出现或增大。本文报道了近期对这些中枢神经系统潜在可治愈肿瘤的治疗经验。对相关文献进行了综述,并讨论了诊断和治疗方面的考虑因素。分析了这种现象可能的免疫机制。总之,疑似患有中枢神经系统结核病的患者应接受延长疗程(12 - 30个月)的有效抗结核治疗。新的颅内结核瘤或现有旧病灶扩大的证据并不表明需要改变抗结核药物方案。在这种情况下,全身性地塞米松作为辅助治疗4至8周是值得且有效的。对于中枢神经系统结核病的急性并发症,如治疗脑积水的分流手术,可能需要进行手术干预。当诊断不明确且在8周内对治疗无反应时,可对疑似结核瘤进行立体定向活检。如果最大的病灶不在脑深部高风险区域,可通过手术完全切除。通过这种综合治疗,大多数病例可获得满意的结果。